Mirxes
PublicMirxes is now publicly traded
The data on this page reflects Mirxes's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
May 23, 2025
Last Round
Debt
Jan 13, 2025
Total Funding Raised
$322.75M
Company Overview
Mirxes operates in Biotech and is based in Singapore. Its recorded funding history includes a Debt round in January 2025.
MiRXES is a healthcare company that develops a diagnostic test platform for the early detection of cancer through microRNA quantification, enabling healthcare professionals to identify the disease at asymptomatic stages.
Sector
Biotech
AI Layer
Application
Mirxes Comparables
Compare Mirxes with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Craif Inc. | 72% | |
| Pharus Diagnostics | 71% | |
| 4D Lifetec | 71% |
For institutional investors. Book with your work email.
Mirxes Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | May 23, 2025 | ||||
| Debt | Jan 13, 2025 | ||||
| Series D | Jul 25, 2023 | ||||
| Series C | Jul 8, 2021 | ||||
| Series A | Nov 27, 2018 | ||||
Seed | Sep 5, 2016 |
For institutional investors. Book with your work email.
Mirxes Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Singapore Health Management | Seed |
| CBC Group | Debt |
| EDBI | Series C |
| CCB International | Series C |
| CCB International Capital Limited | IPO |
| NHH Ventures | Series D |
| Keytone Ventures | Series C |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withOct 17, 2026
Mirxes and NCCS partner through a strategic public-private partnership to develop CIRRHOClear, a non-invasive blood-based test that identifies liver cirrhosis risk before symptoms appear, with the test officially launching in Singapore on Oct 16th '26.
- launchesOct 17, 2026
Mirxes and NCCS launch CIRRHOClear(TM), a non-invasive blood-based miRNA test that identifies liver cirrhosis risk before symptoms appear, in Singapore on Oct 17th '26.
For institutional investors. Book with your work email.
Mirxes Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.